home / stock / vbiv / vbiv news


VBIV News and Press, VBI Vaccines Inc. From 06/07/23

Stock Information

Company Name: VBI Vaccines Inc.
Stock Symbol: VBIV
Market: NASDAQ
Website: vbivaccines.com

Menu

VBIV VBIV Quote VBIV Short VBIV News VBIV Articles VBIV Message Board
Get VBIV Alerts

News, Short Squeeze, Breakout and More Instantly...

VBIV -  VBI Vaccines Announces Poster Presentation at EASL 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-anti...

VBIV - Russell 3000 rejig: InMode, Assertio among healthcare additions; Inovio, Bionano among deletions

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

VBIV - SNDL, Invitae among additions to Russell microcap; Inovio, Bionano among deletions

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

VBIV - VBI Vaccines GAAP EPS of -$3.22, revenue of $0.49M

2023-05-15 09:23:24 ET VBI Vaccines press release ( NASDAQ: VBIV ): Q1 GAAP EPS of -$3.22. Revenue of $0.49M (+276.9% Y/Y). For further details see: VBI Vaccines GAAP EPS of -$3.22, revenue of $0.49M

VBIV - VBI Vaccines Reports First Quarter 2023 Financial Results

PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 90% quarter-over-quarter from Q4 2022 to Q1 2023 as access to PreHevbrio continues to broaden – now available at several U.S. retail pharmacy chains including Costco, RiteAid, and Walmart Therapeutic Hepatitis ...

VBIV - VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI’s Board of Directors. Dr. Himes has a...

VBIV - CRVS, NAAS and GFAI among mid-day movers

2023-04-12 12:55:56 ET Gainers: National CineMedia ( NCMI ) +151% . TESSCO Technologies Incorporated ( TESS ) +87% . Guardforce AI ( GFAI ) +51% . Bullfrog AI Holdings ( BFRG ) +32% . Altamira Therapeutics ( CYTO ) +28% . Tri...

VBIV - Altamira, Arrowhead top healthcare gainers; Cutera, Innovative Eyewear among losers

2023-04-12 10:03:10 ET Gainers: Altamira Therapeutics ( CYTO ) +74% . Arrowhead Pharmaceuticals ( ARWR ) +11% . Procaps Group ( PROC ) +11% . Tempest Therapeutics ( TPST ) +11% . Meihua International Medical Technologies ( MHUA )...

VBIV - VBI Vaccines falls 40% on portfolio reorganization, reverse stock split

2023-04-04 09:52:16 ET Shares of VBI Vaccines ( NASDAQ: VBIV ) lost ~40% in the morning hours Tuesday after announcing a reverse stock split and plans to reduce as much as 30-35% of its internal workforce in conjunction with a portfolio reorganization. "We believe these diff...

VBIV - VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headc...

Previous 10 Next 10